MYCODERM
Brand:
MYCODERM
Manufacturer:
FDC
Manufacturer Details
FDC
Compositions:
Salicylic acid 3% ,
Benzoic acid 6% ,
Starch 31%,
Talc sterilzed q.s.dusting powder ,
MYCODERM-C,
Clotrimazole 1% w/w + starch q.s. dusting powder,
|
Strength
|
Rate
|
Packing Style
|
|
3%+6%+31%
|
97.00
|
150g dusting powder
|
|
1%w/w+
|
92.50
|
100g dusting powder
|
List of Related Indications:
List Of Drugs:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Interacting drugs- summary
Refer -Salicylates
Indication:
Interacting drugs- summary
Refer -Salicylates
Adverse Reaction:
Salicylate intoxification and death(increased risk with large dose, young children, high dose,frequency, presence of occulsion either dressing or natural skin folds). Dermatitis, allergic response, irritation, inflammation. Systemic absorption causes nausea, thirst,sweating, fatigue, fever and confusion.
Contra-Indications:
Hypersens, neonates, lactation, pregnancy. Special ptrecautions: None reported.
Patient Information:
1. For external use only- Avoid contact with eyes, face, genitals, mucous membranes and normal skin surrounding warts.
2. Medication may cause reddening of or scaling of skin when used on open skin lesions.
3. Contact with clothing, fabrics, plastics, wood, metal or other materials may cause damage, avoid contact.
Pharmacology/ Pharmacokinetics:
Pharmacology:
Salicylic acid produces desquamation of the horny layer of the skin, while not affecting the structure of the viable epidermis, by dissolving intercelluar cement substance.
Pharmacokinetics:
Peak serum levels occured within 5 hours of the topical application under occulsion.
Pregnancy and lactation:
Pregnancy No adequate and well controlled studies in pregnant wome. Use with caution.
